Literature DB >> 15869450

Molecular nuclear imaging: the radiopharmaceuticals (review).

Seyed K Imam1.   

Abstract

Application of the nuclear approach for the detection of inherited diseases is an important goal for nuclear medicine and will likely result in an important breakthrough, which will, hopefully, lead to improved diagnoses of genetic defects and objective evaluations of the efficacy of therapeutic strategies. Although still largely in the research realm, molecular imaging is in the process of emerging as a vital component of the diagnosis of disease and monitoring of the therapy. The clinical research in nuclear medicine has made major advancements in the direction of molecular medicine and targeted therapy. In the past few years, exponential achievements have been accomplished in the development of molecular nuclear imaging agents, as described below.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15869450     DOI: 10.1089/cbr.2005.20.163

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  10 in total

1.  Microwave-induced nucleophilic [18F]fluorination on aromatic rings: synthesis and effect of halogen on [18F]fluoride substitution of meta-halo (F, Cl, Br, I)-benzonitrile derivatives.

Authors:  Ning Guo; David Alagille; Gilles Tamagnan; Ronald R Price; Ronald M Baldwin
Journal:  Appl Radiat Isot       Date:  2008-03-10       Impact factor: 1.513

Review 2.  Nanoparticle ligand presentation for targeting solid tumors.

Authors:  Jason T Duskey; Kevin G Rice
Journal:  AAPS PharmSciTech       Date:  2014-06-14       Impact factor: 3.246

3.  Optimization of microfluidic PET tracer synthesis with Cerenkov imaging.

Authors:  Alex A Dooraghi; Pei Y Keng; Supin Chen; Muhammad R Javed; Chang-Jin C J Kim; Arion F Chatziioannou; R Michael van Dam
Journal:  Analyst       Date:  2013-10-07       Impact factor: 4.616

4.  LROC Investigation of Three Strategies for Reducing the Impact of Respiratory Motion on the Detection of Solitary Pulmonary Nodules in SPECT.

Authors:  Mark S Smyczynski; Howard C Gifford; Joyoni Dey; Andre Lehovich; Joseph E McNamara; W Paul Segars; Michael A King
Journal:  IEEE Trans Nucl Sci       Date:  2016-02-15       Impact factor: 1.679

5.  Modeling the respiratory motion of solitary pulmonary nodules and determining the impact of respiratory motion on their detection in SPECT imaging.

Authors:  Mark S Smyczynski; Howard C Gifford; Andre Lehovich; Joseph E McNamara; W Paul Segars; Eric A Hoffman; Benjamin M W Tsui; Michael A King
Journal:  IEEE Trans Nucl Sci       Date:  2016-02-15       Impact factor: 1.679

6.  Could 99mTc-glucarate be used to evaluate tumour necrosis? In vitro and in vivo studies in leukaemic tumour cell line U937.

Authors:  Nathalie Perek; Odile Sabido; Nathalie Le Jeune; Nathalie Prevot; Jean-Michel Vergnon; Anthony Clotagatide; Francis Dubois
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-13       Impact factor: 9.236

7.  On-board SPECT for localizing functional targets: a simulation study.

Authors:  Justin Roper; James Bowsher; Fang-Fang Yin
Journal:  Med Phys       Date:  2009-05       Impact factor: 4.071

8.  Early detection of tumor response by FLT/microPET Imaging in a C26 murine colon carcinoma solid tumor animal model.

Authors:  Wan-Chi Lee; Chih-Hsien Chang; Chung-Li Ho; Liang-Cheng Chen; Yu-Hsien Wu; Jenn-Tzong Chen; Ying-Ling Wang; Te-Wei Lee
Journal:  J Biomed Biotechnol       Date:  2011-08-16

9.  d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution.

Authors:  Marek Pruszynski; Choong Mo Kang; Eftychia Koumarianou; Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Molecules       Date:  2018-05-20       Impact factor: 4.411

10.  (99m)Tc glucarate as a potential radiopharmaceutical agent for assessment of tumor viability: from bench to the bed side.

Authors:  Partha S Choudhury; E Savio; K K Solanki; O Alonso; A Gupta; J P Gambini; Dinesh Doval; P Sharma; M Dondi
Journal:  World J Nucl Med       Date:  2012-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.